Previous close | 157.06 |
Open | 158.79 |
Bid | 168.34 x 1000 |
Ask | 168.90 x 800 |
Day's range | 158.65 - 170.20 |
52-week range | 121.32 - 464.00 |
Volume | |
Avg. volume | 1,610,225 |
Market cap | 40.796B |
Beta (5Y monthly) | -0.28 |
PE ratio (TTM) | 3.22 |
EPS (TTM) | 52.10 |
Earnings date | 08 Aug 2022 |
Forward dividend & yield | 2.11 (1.32%) |
Ex-dividend date | 02 June 2022 |
1y target est | 259.76 |
An overall market rebound and Tuesday's authorization of boosters for kids likely propelled the stock higher.
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.